Entrectinib（恩曲替尼）

Solid tumors
This product is suitable for adults and children aged 12 years and above with solid tumors who meet the following conditions
Diagnosed as carrying neurotrophic tyrosine receptor kinase (NTRK) fusion genes and excluding known acquired resistance mutations by fully validated detection methods
Patients with locally advanced, metastatic disease or patients who may suffer from severe complications due to surgical resection, and patients who have no satisfactory alternative treatment or have failed previous treatment
This indication is conditionally approved for marketing based on alternative endpoints. Clinical endpoint data have not yet been obtained, and the effectiveness and safety are yet to be further confirmed after marketing.